For Immediate Release:

Stephen C. Schimpff, M.D. FACP Appointed to SteriView Inc. Board of Directors

SAUSALITO, Calif., March 31, 2016 - SteriView, Inc., (http://steriviewinc.com) today announced that Stephen C. Schimpff, M.D., FACP has joined the Company’s Board of Directors.

Dr. Schimpff is the retired Chief Executive Officer of the University of Maryland Medical Center and the former Chair of the Board of Governors of the National Institutes of Health’s (NIH) Warren G. Magnuson Clinical Center and the founding Director of the University of Maryland’s Greenebaum Cancer Center.

“SteriView is very pleased to have Dr. Schimpff on the Company’s Board,” said Larry Gerrans, Founder and Chairman of SteriView. “Dr. Schimpff brings a wealth of scientific knowledge, industry expertise and business acumen to SteriView. His achievements in science and medicine place him among the elite intellectuals and leaders of our time. We appreciate Dr. Schimpff’s willingness to serve and look forward to benefitting from his experience and wise counsel.”

Internationally recognized for his research into the causes, prevention and treatment of infection in cancer patients undergoing aggressive cancer therapy, Dr. Schimpff has published more than 200 scientific articles, reviews and book chapters.

He has written four books, including "The Future of Medicine: Megatrends in Healthcare," "The Future of Health-Care Delivery: Why It Must Change and How It Will Affect You," and "Alignment – The Key to Success of the University of Maryland Medical System" and “Fixing The Primary Care Crisis.“ He has co-edited three text books, including "Comprehensive Textbook of Oncology", "Handbook of Supportive Care in Cancer," and “Infectious Complications in Bone Marrow Transplantations.”

Dr. Schimpff also worked as a consultant for the Army's Telemedicine and Advanced Technology Research Center (TATRC) to develop their strategic plan and specific tactics around SteriViewty, especially in the operating room.

“I admire SteriView for its innovative products and dynamic leadership team and I am honored to be joining their board,” related Dr. Schimpff. “I have tremendous respect for Larry and his team, and I look forward to working with SteriView as it develops and offers new technologies to the medical field that will have a real impact.”

Dr. Schimpff has long been engaged in ways to reduce hospital acquired infections from most every perspective and position in the health care delivery system. Beginning with his earliest career endeavors as a medical oncologist and infectious disease clinician and researcher with the National Cancer Institute (NCI) Dr. Schimpff received broad acclaim and recognition for his multiple peer reviewed articles relating his seminal works with aggressively treated cancer patients suffering with compromised immune systems, specifically those with acute leukemia.

His essential work continued as the Head of Infectious Diseases at the University of Maryland Medical System and as Founding Director of the University of Maryland Greenebaum Cancer Center. As his leadership and oversight grew, in his capacities as Chief Operating Officer and Chief Executive Officer of the University of Maryland Medical Center, Dr. Schimpff lead 5,000 staff, 650 residents and oversaw an annual budget of over $1 billion in treating over 40,000 patients per year and leading the world’s preeminent trauma center, an NCI designated cancer center and one of the country’s largest transplant programs.

About SteriView, Inc. (http://steriviewinc.com)

SteriView’s new class of inspection scopes offer cost effective inspection of medical instruments, and recording and documentation of inspection results to address the serious problem of avoidable device-associated infections. Reprocessed instruments play an essential part of the enormous numbers of procedures (approximately 14 million colonoscopies, 1.7 million arthroscopies, 2.5 million laparoscopies in the US, annually). Healthcare associated infections affect 1.7 million Americans every year with upwards of 100,000 deaths and are estimated to cost $20 to $35 billion in excess healthcare costs and up to $35 billion in lost productivity, annually, in the US alone. SteriView’s technologies offer institutions a practical method of risk management, process improvement, and infection control.

Contact:

Steve Goldsmith
SteriView
415-729-9391 x1023
This email address is being protected from spambots. You need JavaScript enabled to view it.

# # #